PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients.

Abstract With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and improves the curative effect. A series of randomized phase III trials are ongoing. In this review, we discuss the prospect and current situation of immune checkpoint inhibitors in first-line treatment in advanced NSCLC patients.
PMID
Related Publications

Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.

Immune checkpoint inhibitors in NSCLC.

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer.

Immune checkpoint modulation for non-small cell lung cancer.

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

Authors

Mayor MeshTerms
Keywords
Journal Title zhongguo fei ai za zhi = chinese journal of lung cancer
Publication Year Start




PMID- 28641702
OWN - NLM
STAT- MEDLINE
DA  - 20170623
DCOM- 20170630
LR  - 20170630
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 20
IP  - 6
DP  - 2017 Jun 20
TI  - [Prospect and Current Situation of Immune Checkpoint Inhibitors in First-line
      Treatment in Advanced Non-small Cell Lung Cancer Patients].
PG  - 427-432
LID - 10.3779/j.issn.1009-3419.2017.06.10 [doi]
AB  - With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors
      monotherapy as first-line and second-line treatment in advanced non-small cell
      lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing.
      Immune combination therapy expands the benefit population and improves the
      curative effect. A series of randomized phase III trials are ongoing. In this
      review, we discuss the prospect and current situation of immune checkpoint
      inhibitors in first-line treatment in advanced NSCLC patients.
FAU - Wang, Haiyang
AU  - Wang H
AD  - Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou
      310053, China.
FAU - Yu, Xiaoqing
AU  - Yu X
AD  - Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou
      310053, China.
FAU - Fan, Yun
AU  - Fan Y
AD  - Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou
      310053, China.
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/physiopathology
MH  - Cell Cycle Checkpoints/*drug effects
MH  - Humans
MH  - Immunologic Factors/*administration & dosage
MH  - Lung Neoplasms/*drug therapy/immunology/physiopathology
MH  - Randomized Controlled Trials as Topic
EDAT- 2017/06/24 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/24 06:00
AID - 10.3779/j.issn.1009-3419.2017.06.10 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):427-432. doi:
      10.3779/j.issn.1009-3419.2017.06.10.